Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage

Investigative Ophthalmology and Visual Science

Volumn 47, Issue 3, 2006, Pages 1149-1160

  Amrite, Aniruddha C ^a   Ayalasomayajula, Surya P ^c   Cheruvu, Narayan P S ^a   Kompella, Uday B ^a,b,d  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; GLUCOSE; POLYGLACTIN; PROSTAGLANDIN E2; STREPTOZOCIN; VASCULOTROPIN; DRUG CARRIER; LACTIC ACID; MESSENGER RNA; MICROSPHERE; POLYGLYCOLIC ACID; POLYLACTIC ACID POLYGLYCOLIC ACID COPOLYMER; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; POLYMER; PROSTAGLANDIN SYNTHASE INHIBITOR; PYRAZOLE DERIVATIVE; SULFONAMIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, HUMAN; VASCULAR ENDOTHELIAL GROWTH FACTOR A, RAT; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

ANESTHESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CELL COUNT; BLOOD CHEMISTRY; BLOOD RETINA BARRIER; BODY WEIGHT; CONTROLLED STUDY; CYTOTOXICITY; DIABETES MELLITUS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG RELEASE; DRUG SAFETY; DRUG TISSUE LEVEL; ENCAPSULATION; GAMMA IRRADIATION; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; INSTRUMENT STERILIZATION; MALE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; PROTEIN EXPRESSION; RAT; RETINA; STREPTOZOCIN DIABETES; VITREOUS BODY; ANIMAL; CAPILLARY PERMEABILITY; CULTURE TECHNIQUE; DIABETIC RETINOPATHY; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; GENETICS; INJECTION; METABOLISM; PIGMENT EPITHELIUM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT;

ANIMALS; BLOOD-RETINAL BARRIER; CAPILLARY PERMEABILITY; CELL CULTURE TECHNIQUES; CYCLOOXYGENASE INHIBITORS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; DINOPROSTONE; DRUG CARRIERS; HUMANS; INJECTIONS; LACTIC ACID; MALE; MICROSPHERES; PIGMENT EPITHELIUM OF EYE; POLYGLYCOLIC ACID; POLYMERS; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SULFONAMIDES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33645403444     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.05-0531     Document Type: Article

References (78)

1. Niitsu Y, Takayama T, Miyanishi K, et al. Chemoprevention of colorectal cancer. Cancer Chemother Pharmacol. 2004;54(suppl 1):S40-S43.
2. Koehne CH, Dubois RN. COX-2 inhibition and colorectal cancer. Semin Oncol. 2004;31:12-21.
3. Guastalla JP, Bachelot T, Ray-Coquard I. Cyclooxygenase 2 and breast cancer. From biological concepts to therapeutic trials [in French]. Bull Cancer. 2004;91:S99-S108.
4. Spano JP, Chouahnia K, Morere JF. Cyclooxygenase 2 inhibitors and lung carcinoma [in French]. Bull Cancer. 2004;91:S109-S12.
5. Basler JW, Piazza GA. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention. J Urol. 2004;171:S59-S62; discussion S62-S63.
6. Du Y, Sarthy VP, Kern TS. Interaction between NO and COX pathways in retinal cells exposed to elevated glucose and retina of diabetic rats. Am J Physiol. 2004;287:R735-R741.
7. Ayalasomayajula SP, Amrite AC, Kompella UB. Inhibition of cyclooxygenase-2, but not cyclooxygenase-1, reduces prostaglandin E2 secretion from diabetic rat retinas. Eur J Pharmacol. 2004;498:275-278.
8. Saishin Y, Takahashi K, Melia M, Vinores SA, Campochiaro PA. Inhibition of protein kinase C decreases prostaglandin-induced breakdown of the blood-retinal barrier. J Cell Physiol. 2003;195:210-219.
9. Derevjanik NL, Vinores SA, Xiao WH, et al. Quantitative assessment of the integrity of the blood-retinal barrier in mice. Invest Ophthalmol Vis Sci. 2002;43:2462-2467.
10. Ayalasomayajula SP, Kompella UB. Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. Eur J Pharmacol. 2003;458:283-289.
11. Xu X, Zhu Q, Xia X, Zhang S, Gu Q, Luo D. Blood-retinal barrier breakdown induced by activation of protein kinase C via vascular endothelial growth factor in streptozotocin-induced diabetic rats. Curr Eye Res. 2004;28:251-256.
12. Hammes HP, Lin J, Bretzel RG, Brownlee M, Breier G. Upregulation of the vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat. Diabetes. 1998;47:401-406.
13. Itakura H, Kishi S, Kotajima N, Murakami M. Persistent secretion of vascular endothelial growth factor into the vitreous cavity in proliferative diabetic retinopathy after vitrectomy. Ophthalmology. 2004;111:1880-1884.
14. Watanabe D, Suzuma K, Suzuma I, et al. Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Am J Ophthalmol. 2005;139:476-481.
15. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480-1487.
16. Abdel-Majid RM, Marshall JS. Prostaglandin E2 induces degranulation-independent production of vascular endothelial growth factor by human mast cells. J Immunol. 2004;172:1227-1236.
17. Casibang M, Purdom S, Jakowlew S, et al. Prostaglandin E2 and vasoactive intestinal peptide increase vascular endothelial cell growth factor mRNAs in lung cancer cells. Lung Cancer. 2001;31:203-212.
18. Cheng T, Cao W, Wen R, Steinberg RH, LaVail MM. Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Muller cells. Invest Ophthalmol Vis Sci. 1998;39:581-591.
19. Fukuda R, Kelly B, Semenza GL. Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1. Cancer Res. 2003;63:2330-2334.
20. Inoue H, Takamori M, Shimoyama Y, Ishibashi H, Yamamoto S, Koshihara Y. Regulation by PGE2 of the production of interleukin-6, macrophage colony stimulating factor, and vascular endothelial growth factor in human synovial fibroblasts. Br J Pharmacol. 2002;136:287-295.
21. Pai R, Szabo IL, Soreghan BA, Atay S, Kawanaka H, Tarnawski AS. PGE(2) stimulates VEGF expression in endothelial cells via ERK2/JNK1 signaling pathways. Biochem Biophys Res Commun. 2001;286:923-928.
22. Trompezinski S, Pernet I, Schmitt D, Viac J. UV radiation and prostaglandin E2 up-regulate vascular endothelial growth factor (VEGF) in cultured human fibroblasts. Inflamm Res. 2001;50:422-427.
23. Murata T, Nakagawa K, Khalil A, Ishibashi T, Inomata H, Sueishi K. The relation between expression of vascular endothelial growth factor and breakdown of the blood-retinal barrier in diabetic rat retinas. Lab Invest. 1996;74:819-825.
24. Sennlaub F, Valamanesh F, Vazquez-Tello A, et al. Cyclooxygenase-2 in human and experimental ischemic proliferative retinopathy. Circulation. 2003;108:198-204.
25. Solomon DH, Schneeweiss S, Levin R, Avorn J. Relationship between COX-2 specific inhibitors and hypertension. Hypertension. 2004;44:140-145.
26. Kammerl MC, Debler J, Riegger GA, Kramer BK. COX-2 inhibitors and risk of heart failure (Letter). Lancet. 2004;364:1486-1487;author reply 1487.
27. FitzGerald GA, Cheng Y, Austin S. COX-2 inhibitors and the cardiovascular system. Clin Exp Rheumatol. 2001;19:S31-S36.
28. Raghava S, Hammond M, Kompella UB. Periocular routes for retinal drug delivery. Expert Opin Drug Deliv. 2004;1:99-114.
29. Ayalasomayajula SP, Kompella UB. Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration. Pharm Res. 2004;21:1797-1804.
30. Kompella UB, Bandi N, Ayalasomayajula SP. Subconjunctival nanoand microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Invest Ophthalmol Vis Sci. 2003;44:1192-1201.
31. Ayalasomayajula SP, Kompella UB. Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model. Eur J Pharmacol. 2005;511:191-198.
32. Amrite AC, Kompella UB. Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration. J Pharm Pharmacol. 2005;57:1555-1563.
33. Ayalasomayajula SP, Kompella UB. Induction of vascular endothelial growth factor by 4-hydroxynonenal and its prevention by glutathione precursors in retinal pigment epithelial cells. Eur J Pharmacol. 2002;449:213-220.
34. Wang XF, Cui JZ, Prasad SS, Matsubara JA. Altered gene expression of angiogenic factors induced by calcium-mediated dissociation of retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 2005;46:1508-1515.
35. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402-408.
36. Ottino P, Finley J, Rojo E, et al. Hypoxia activates matrix metalloproteinase expression and the VEGF system in monkey choroidretinal endothelial cells: Involvement of cytosolic phospholipase A2 activity. Mol Vis. 2004;17:341-350.
37. Martinez-Sancho C, Herrero-Vanrell R, Negro S. Study of gamma-irradiation effects on aciclovir poly(D,L-lactic-co-glycolic) acid microspheres for intravitreal administration. J Control Release. 2004;99:41-52.
38. Ishida S, Usui T, Yamashiro K, et al. VEGF164 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci. 2003;44:2155-2162.
39. Joussen AM, Poulaki V, Le ML, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 2004;18:1450-1452.
40. Joussen AM, Murata T, Tsujikawa A, Kirchhof B, Bursell SE, Adamis AP. Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am J Pathol. 2001;158:147-152.
41. Joussen AM, Poulaki V, Mitsiades N, et al. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J. 2002;16:438-440.
42. Kern TS, Engerman RL. Pharmacological inhibition of diabetic retinopathy: aminoguanidine and aspirin. Diabetes. 2001;50:1636-1642.
43. Saishin Y, Silva RL, Saishin Y, et al. Periocular injection of microspheres containing PKC412 inhibits choroidal neovascularization in a porcine model. Invest Ophthalmol Vis Sci. 2003;44:4989-4993.
44. Bresnick GH. Diabetic macular edema: a review. Ophthalmology. 1986;93:989-997.
45. Gallin JI, Synderman R, eds. Inflammation. Philadelphia: Lippincott Williams & Wilkins; 1999.
46. Garner A. Histopathology of diabetic retinopathy in man. Eye. 1993;7:250-253.
47. Miyamoto K, Ogura Y. Pathogenetic potential of leukocytes in diabetic retinopathy. Semin Ophthalmol. 1999;14:233-239.
48. Vinores SA. Assessment of blood-retinal barrier integrity. Histol Histopathol. 1995;10:141-154.
49. Carmo A, Cunha-Vaz JG, Carvalho AP, Lopes MC. Effect of cyclosporin-A on the blood-retinal barrier permeability in streptozotocin-induced diabetes. Mediators Inflamm. 2000;9:243-248.
50. Atkinson EG, Jones S, Ellis BA, Dumonde DC, Graham E. Molecular size of retinal vascular leakage determined by FITC-dextran angiography in patients with posterior uveitis. Eye. 1991;5:440-446.
51. Tolentino MJ, Husain D, Theodosiadis P, et al. Angiography of fluoresceinated anti-vascular endothelial growth factor antibody and dextrans in experimental choroidal neovascularization. Arch Ophthalmol. 2000;118:78-84.
52. Miyahara S, Kiryu J, Yamashiro K, et al. Simvastatin inhibits leukocyte accumulation and vascular permeability in the retinas of rats with streptozotocin-induced diabetes. Am J Pathol. 2004;164:1697-1706.
53. Stitt AW, Bhaduri T, McMullen CB, Gardiner TA, Archer DB. Advanced glycation end products induce blood-retinal barrier dysfunction in normoglycemic rats. Mol Cell Biol Res Commun. 2000;3:380-388.
54. Shires TK, Faeth JA, Pulido JS. Protein levels in the vitreous of rats with streptozotocin-induced diabetes mellitus. Brain Res Bull. 1993;30:85-90.
55. Paulson SK, Zhang JY, Breau AP, et al. Pharmacokinetics, tissue distribution, metabolism, and excretion of celecoxib in rats. Drug Metab Dispos. 2000;28:514-521.
56. Aiello LP, Northrup JM, Keyt BA, Takagi H, Iwamoto MA. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol. 1995;113:1538-1544.
57. Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol. 1994;118:445-450.
58. Duh EJ, Yang HS, Haller JA, et al. Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor: implications for ocular angiogenesis. Am J Ophthalmol. 2004;137:668-674.
59. Aukunuru JV, Sunkara G, Ayalasomayajula SP, DeRuiter J, Clark RC, Kompella UB. A biodegradable injectable implant sustains systemic and ocular delivery of an aldose reductase inhibitor and ameliorates biochemical changes in a galactose-fed rat model for diabetic complications. Pharm Res. 2002;19:278-285.
60. Adamis AP, Shima DT, Yeo KT, et al. Synthesis and secretion of vascular permeability factor/vascular endothelial growth factor by human retinal pigment epithelial cells. Biochem Biophys Res Commun. 1993;193:631-638.
61. Yoshino T, Kimoto A, Kobayashi S, et al. Pharmacological profile of celecoxib, a specific cyclooxygenase-2 inhibitor (in German). Arzneimittelforschung. 2005;55:394-402.
62. Smith CJ, Zhang Y, Koboldt CM, et al. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci USA. 1998;95:13313-13318.
63. Liu XH, Kirschenbaum A, Lu M, et al. Prostaglandin E2 induces hypoxia-inducible factor-1alpha stabilization and nuclear localization in a human prostate cancer cell line. J Biol Chem. 2002;277:50081-50086.
64. Liu LX, Lu H, Luo Y, et al. Stabilization of vascular endothelial growth factor mRNA by hypoxia-inducible factor 1. Biochem Biophys Res Commun. 2002;291:908-914.
65. Reddy MN, Rehana T, Ramakrishna S, Chowdhary KP, Diwan PV. Beta-cyclodextrin complexes of celecoxib: molecular-modeling, characterization, and dissolution studies. AAPS PharmSci. 2004;6:E7.
66. Gupta P, Chawla G, Bansal AK. Physical stability and solubility advantage from amorphous celecoxib: the role of thermodynamic quantities and molecular mobility. Mol Pharm. 2004;1:406-413.
67. Seedher N, Bhatia S. Solubility enhancement of Cox-2 inhibitors using various solvent systems. AAPS PharmSciTech. 2003;4:E33.
68. Qaum T, Xu Q, Joussen AM, et al. VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci. 2001;42:2408-2413.
69. Battegay EJ. Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J Mol Med. 1995;73:333-346.
70. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyper-permeability, and angiogenesis. Am J Pathol. 1995;146:1029-1039.
71. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA. 1995;92:905-909.
72. Senger DR, Connolly DT, Van de Water L, Feder J, Dvorak HF. Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res. 1990;50:1774-1778.
73. Kosaka T, Mishima HK, Kiuchi Y, Kataoka K. The effects of prostaglandins on the blood-ocular barrier. Jpn J Ophthalmol. 1995;39:368-376.
74. Naveh N, Weissman C. The correlation between excessive vitreal protein levels, prostaglandin E2 levels, and the blood-retinal barrier. Prostaglandins. 1990;39:147-156.
75. Bates DO, Cui TG, Doughty JM, et al. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res. 2002;62:4123-4131.
76. Cui TG, Foster RR, Saleem M, et al. Differentiated human podocytes endogenously express an inhibitory isoform of vascular endothelial growth factor (VEGF165b) mRNA and protein. Am J Physiol. 2004;286:F767-F773.
77. Woolard J, Wang WY, Bevan HS, et al. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res. 2004;64:7822-7835.
78. Kimura H, Ogura Y, Moritera T, et al. Injectable microspheres with controlled drug release for glaucoma filtering surgery. Invest Ophthalmol Vis Sci. 1992;33:3436-3441.